Steven Chapman - Natera CEO Director
| NTRA Stock | USD 173.39 2.66 1.56% |
CEO
Mr. Steven Leonard Chapman is President, Chief Executive Officer, Director of the Company. he served as Senior Vice President Commercial Operations of Natera, Inc. Mr. Chapman began his career in the Department of Human Genetics at UCLA, where he contributed to the selection process and design of oligonucleotide arrays used to identify SNPs associated with multiple sclerosis. After leaving UCLA, Mr. Chapman worked in a commercial role with Genzyme Genetics, where his team was responsible for prenatal and preconception genetic testing revenues nearing 100 million. During his time at Genzyme, Mr. Chapmans efforts reshaped the way medicine is practiced when he led Genzymes sales initiative into population screening for Fragile X Syndrome. He established the largest global network of physicians who routinely screen for the disorder, and radically altered the way the test is offered. In 2005, he elevated carrier screening for Spinal Muscular Atrophy to the forefront of business development efforts at Genzyme, playing a critical role in the groundbreaking launch of SMA carrier screening. Today, SMA screening is recommended by the ACMG and is routinely offered to couples across the United States. At Genzyme, Mr. Chapman was the direct recipient of 27 sales awards and was a twotime winner of the prestigious Alpine Award, which recognizes outstanding achievement and innovation. Since joining Natera in 2010, he was responsible for building Nateras sales and managedcare teams and has also led the commercial team. He has also overseen the successful launch of five products and the establishment of the premier worldwide distribution network for noninvasive prenatal testing since 2019.
| Age | 46 |
| Tenure | 6 years |
| Address | 13011 McCallen Pass, Austin, TX, United States, 78753 |
| Phone | 650 980 9190 |
| Web | https://www.natera.com |
Steven Chapman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Chapman against Natera stock is an integral part of due diligence when investing in Natera. Steven Chapman insider activity provides valuable insight into whether Natera is net buyers or sellers over its current business cycle. Note, Natera insiders must abide by specific rules, including filing SEC forms every time they buy or sell Natera'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Chapman over three months ago Disposition of 4523 shares by Steven Chapman of Natera at 130.3995 subject to Rule 16b-3 | ||
Steven Chapman over six months ago Disposition of 18750 shares by Steven Chapman of Natera at 25.46 subject to Rule 16b-3 | ||
Steven Chapman over six months ago Disposition of 2662 shares by Steven Chapman of Natera at 90.4158 subject to Rule 16b-3 | ||
Steven Chapman over six months ago Disposition of 6711 shares by Steven Chapman of Axalta Coating subject to Rule 16b-3 |
Natera Management Efficiency
The company has return on total asset (ROA) of (0.0996) % which means that it has lost $0.0996 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2582) %, meaning that it created substantial loss on money invested by shareholders. Natera's management efficiency ratios could be used to measure how well Natera manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2025, Return On Tangible Assets is expected to decline to -0.29. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Natera's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 221.2 M, whereas Intangible Assets are forecasted to decline to about 1.8 M.Similar Executives
| Found 10 records | CEO Age | ||
| Evguenia MBA | Sera Prognostics | 51 | |
| John Hanna | Caredx Inc | 45 | |
| Helmy Eltoukhy | Guardant Health | 46 | |
| John Adent | Neogen | 57 | |
| Jacob Thaysen | Illumina | 50 | |
| Peter Maag | Caredx Inc | 58 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
| Thierry Bernard | Qiagen NV | 61 | |
| Derek Maetzold | Castle Biosciences | 63 | |
| Christopher Hall | Personalis | 56 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0996 |
Natera Inc Leadership Team
Elected by the shareholders, the Natera's board of directors comprises two types of representatives: Natera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Natera. The board's role is to monitor Natera's management team and ensure that shareholders' interests are well served. Natera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Natera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, Chief Officer | ||
| Olesya CPA, Chief Officer | ||
| LLM LLM, S Officer | ||
| Jonathan MEng, CoFounder Director | ||
| Sheetal Parmar, Head Services | ||
| Rishi Kacker, Chief Officer | ||
| Phil Grinnell, Vice Sales | ||
| John Fesko, President Officer | ||
| MD MBA, GM Officer | ||
| Anu MS, Head Management | ||
| Robert Schueren, Chief Officer | ||
| Steven Chapman, CEO Director | ||
| Daniel LLM, Secretary Officer | ||
| Solomon MBA, President Diagnostics | ||
| Eric Evans, Chief Officer | ||
| Jerry Diffley, Chief Officer | ||
| Matthew Rabinowitz, Co-Founder, Chairman, CEO and Pres |
Natera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Natera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0996 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 22.44 B | ||||
| Shares Outstanding | 132.02 M | ||||
| Shares Owned By Insiders | 4.31 % | ||||
| Shares Owned By Institutions | 95.52 % | ||||
| Number Of Shares Shorted | 4.46 M | ||||
| Price To Earning | (4.74) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Natera Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Natera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Natera Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Natera Inc Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Natera Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Natera. If investors know Natera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Natera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 0.639 | Return On Assets | Return On Equity |
The market value of Natera Inc is measured differently than its book value, which is the value of Natera that is recorded on the company's balance sheet. Investors also form their own opinion of Natera's value that differs from its market value or its book value, called intrinsic value, which is Natera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Natera's market value can be influenced by many factors that don't directly affect Natera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Natera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Natera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Natera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.